Search results
Results from the WOW.Com Content Network
[10] Amlodipine was patented in 1982, and approved for medical use in 1990. [12] It is on the World Health Organization's List of Essential Medicines. [13] It is available as a generic medication. [10] [14] In 2022, it was the fifth most commonly prescribed medication in the United States, with more than 70 million prescriptions. [15] [16] In ...
Lipoatrophy occurs in HIV-associated lipodystrophy, one cause of which is an adverse drug reaction that is associated with some antiretroviral medications. [2] A more general term for an abnormal or degenerative condition of the entire body's adipose tissue is lipodystrophy.
Lipoatrophy is most commonly seen in patients treated with thymidine analogues and other older HIV drug treatments such as the nucleoside reverse transcriptase inhibitors [NRTIs] [9] like zidovudine (AZT) and stavudine (d4T). [10] Other lipodystrophies manifest as lipid redistribution, with excess, or lack of, fat in various regions of the body ...
Mean absolute bioavailability of a 20 mg dose is 9.6% (range: 4.0 to 16.1%). Peak plasma concentrations (C max) occur between 5 and 6 hours post-dose. Mean C max increases greater than dose-proportionally; a 3-fold and 4-fold increase in C max was observed for dose increases from 20 mg to 40 mg and from 20 mg to 60 mg, respectively.
[5] Tizanidine demonstrates anti-hypertensive effects and should be avoided in patients taking isradipine due to the possibility of synergism between both medications. [6] The antibiotic rifampin lowered plasma concentrations of isradipine to below detectable limits. [2] Cimetidine increased isradipine mean peak plasma levels.
[2] Lovastatin was patented in 1979 and approved for medical use in 1987. [4] It is on the World Health Organization's List of Essential Medicines. [5] It is available as a generic medication. [2] In 2022, it was the 111th most commonly prescribed medication in the United States, with more than 5 million prescriptions. [6] [7]
Absorption of drug is modestly decreased when taken with food however this does not reduce the clinical lipid-lowering effect. [1] The 3α-hydroxyisomeric metabolite of pravastatin is also an active HMG-CoA reductase inhibitor with approximately 2.5-10% the potency of the parent compound.
The drug acts more slowly than older dihydropyridines. [citation needed] It probably has fewer adverse effects, but a comparatively high potential for drug interactions. It was patented in 1984 and first approved for medical use in 1997. [2] The US FDA refused to approve the drug, and lercanidipine is not marketed in USA. [3]